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Abstract: Latent transforming growth factor-β-1 binding protein-2 (LTBP-2) belongs to the
LTBP-fibrillin superfamily of extracellular proteins. Unlike other LTBPs, LTBP-2 does not covalently
bind transforming growth factor-β1 (TGF-β1) but appears to be implicated in the regulation of TGF-β1
bioactivity, although the mechanisms are largely unknown. In experiments originally designed to
study the displacement of latent TGF-β1 complexes from matrix storage, we found that the addition
of exogenous LTBP-2 to cultured human MSU-1.1 fibroblasts caused an increase in TGF-β1 levels
in the medium. However, the TGF-β1 increase was due to an upregulation of TGF-β1 expression
and secretion rather than a displacement of matrix-stored TGF-β1. The secreted TGF-β1 was mainly
in an inactive form, and its concentration peaked around 15 h after addition of LTBP-2. Using a
series of recombinant LTBP-2 fragments, the bioactivity was identified to a small region of LTBP-2
consisting of an 8-Cys motif flanked by four epidermal growth factor (EGF)-like repeats. The LTBP-2
stimulation of TGF-β expression involved the phosphorylation of both Akt and p38 mitogen-activated
protein kinase (MAPK) signalling proteins, and specific inactivation of each protein individually
blocked TGF-β1 increase. The search for the cell surface receptor mediating this LTBP-2 activity
proved inconclusive. Inhibitory antibodies to integrins β1 and αVβ5 showed no reduction of LTBP-2
stimulation of TGF-β1. However, TGF-β1 upregulation was partially inhibited by anti-αVβ3 integrin
antibodies, suggestive of a direct or indirect role for this integrin. Overall, the study indicates that
LTBP-2 can directly upregulate cellular TGF-β1 expression and secretion by interaction with cells
via a short central bioactive region. This may be significant in connective tissue disorders involving
aberrant TGF-β1 signalling.
Keywords: LTBP-2; TGF-β; fibroblast; p38 MAPK; Akt; fibrosis
1. Introduction
Transforming growth factor-β (TGF-β) is a cytokine that exists as three isoforms (TGF-β1, TGF-β2,
and TGF-β3) and regulates numerous physiological processes, including cell growth, differentiation,
adhesion, apoptosis, and modulation of extracellular matrix [1,2]. TGF-β can act as a growth inhibitor
in some cells, including keratinocytes and lung epithelial cells, but can also promote growth in cells
such as smooth muscle cells, mesodermal cells, and fibroblasts [3,4]. When over-expressed, TGF-β
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exhibits pro-fibrotic effects, including excess matrix production, transdifferentiation of fibroblasts into
myofibroblasts, and inhibition of apoptosis, contributing to fibrotic diseases such as pulmonary fibrosis,
liver cirrhosis, and keloid scar formation [5,6]. Disturbance of TGF-β pathways is also associated with
other pathological states, including tumour cell growth, cancer, and autoimmune diseases [7]. TGF-β
null mice die shortly after birth due to developmental abnormalities and excessive inflammatory
response in the heart and lungs [8].
TGF-β is synthesized as a small latent complex of dimers of TGF-β non-covalently bound to its
pro-peptide, called the latency-associated peptide. This small complex can bind covalently to latent
transforming growth factor-β-1 binding proteins (LTBPs), forming the large latent complex [9]. The
large latent complex controls the storage and activation of latent TGF-β by binding to fibrillin-rich
microfibrils in the extracellular matrix [10]. The LTBP/fibrillin superfamily (LTBPs 1–4 and fibrillins
1–3) have similar structures, consisting predominantly of tandem epidermal growth factor (EGF)-like
6-cysteine repeats interspersed with characteristic 8-cysteine motifs [10,11]. Unlike other LTBPs, LTBP-2
is unable to associate and bind covalently to latent TGF-β, since it lacks the required binding consensus
sequence [12,13]. The function of LTBP-2 is poorly understood, although it is expressed abundantly in
tissues such as lung, heart, aorta, placenta, liver, and skeletal muscle tissues [14,15]. LTBP-2 null mice
were originally reported to die during embryo implantation [16]. However, a LTBP-2 null strain has
recently been reported that survives to adulthood with lens luxation caused by an abnormal formation
of fibrillin-rich ciliary zonules [17], which is consistent with the mild ocular phenotypes shown by
LTBP-2 null humans [18,19]. LTBP2 gene mutations have been linked to Weill–Marchesani syndrome
(WMS) [20], characterized by ocular and skeletal deformities and thick fibrotic skin, containing
disorganised fibrillin-1 microfibrillar networks. FBN1 gene mutations also cause WMS [21], indicating
that the disease mechanism involves both proteins. Fibrillin-1 modulation of TGF-β storage and
activation is well-documented [1,22,23]. Thus, it is possible that LTBP-2 may also influence TGF-β
bioavailability, supported by observations that some individuals with LTBP-2 mutations exhibit Marfan
Syndrome-like characteristics linked to aberrant TGF-β upregulation [18,19]. LTBP-2 may also be
involved in the regulation of latent TGF-β storage and activation in the extracellular matrix. In a rat
model, the treatment of astrocytes with antisense LTBP-2 oligonucleotides resulted in a downregulation
of both LTBP-2 mRNA expression and TGF-β activity, strongly suggesting that LTBP-2 may regulate
TGF-β activation [24]. Hirani, Hanssen, and Gibson [14] reported that LTBP-2 specifically binds to
fibrillin-1 rather than fibrillin-2 and that a C-terminal fragment of LTBP-2 blocks the interaction of
LTBP-1 with fibrillin-1 in vitro [14]. These findings led to the hypothesis that LTBP-2 might indirectly
regulate TGF-β bioavailability by releasing LTBP-1 from microfibrils through competitive binding
for fibrillin-1.
Given this evidence, it seems clear that LTBP-2 plays some role in regulating TGF-β bioactivity,
but the mechanism remains unclear. In this paper, we report that a central bioactive region of LTBP-2
can upregulate TGF-β1 expression in fibroblasts and that the mechanism involves both Akt and p38
mitogen-activated protein kinase (MAPK) signalling pathways. The cell surface receptor(s) involved
in the upregulation remain(s) undefined, but may be complexed with αVβ3 integrin.
2. Results
2.1. Exogenous LTBP-2 Stimulates Expression and Secretion of TGF-β1 in MSU-1.1 Fibroblasts
To study the potential role of LTBP-2 in the modulation of TGF-β matrix storage and activation,
MSU-1.1 cells were selected since these cells have high levels of expression of fibrillin-1, LTBP-1, and
TGF-β1 but low expression of LTBP-2, and the cells form an extensive fibrillin microfibril network [25].
The initial experiment was designed to determine if LTBP-2 could displace LTBP-1/TGF-β1 complexes
from their attachment to fibrillin microfibrils. MSU-1.1 cells were cultured to 3 weeks post-confluence,
to allow for the formation of an extensive extracellular matrix rich in fibrillin-1 microfibrils. After
incubation with exogenous LTBP-2 for 16 h, TGF-β1 was significantly elevated in the medium, with
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an approximately threefold increase compared to control cells incubated with bovine serum albumin
(BSA) (Figure 1A). However, the TGF-β1 content of the cell layer showed no significant difference
between treated and control cultures, indicating that the increase in TGF-β1 may represent a newly
synthesised protein rather than protein displaced from the microfibrils in the matrix.
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Figure 1. Exogenous latent transforming growth factor-β-1 binding protein-2 (LTBP-2) increases
transforming growth factor-β1 (TGF-β1) in conditioned medium, which is independent of extracellular
matrix. (A) MSU-1.1 cells were cultured for 24 h or 3 weeks post-confluence, then incubated in
serum-free medium overnight containing 10 µg/mL LTBP-2 (black columns) or bovine serum albumin
(BSA) control (grey columns) prior to TGF-β1 assay. Total TGF-β in the conditioned medium and cell
layer was easured by ELISA (see Materials and Methods). LTBP-2 caused a significant increase in
TGF-β1 without the presence of extensive extracellular matrix; (B) The secreted TGF-β1 is mainly in
an inactive for . The med um from 3-week post-confluence LTBP-2- reated cultures was analysed
with and without cid treatme t for total n active TGF-β1, respectively. Approximately 70% of
the TGF-β1 in the condition d medium was i active. Quantified data are xpressed as me n ± SD
(standard deviation). Statistical significance was determined by paired Student’s t test, * p < 0.05.
To test this idea, exogenous LTBP-2 was added to MSU-1.1 cells grown for only 24 h
post-confluence such that only minimal fibrillin microfibrils would be present [26]. Again, TGF-β1
was highly elevated in the medium relative to control cultures, but there was little difference in cell
layer between the treated and control cells (Figure 1A). An analysis of the TGF-β1 released into the
medium of 3 weeks post-confluence cultures indicated that approximately 70% of the TGF-β1 was in
latent (complexed) form (Figure 1B). The addition of LTBP-2 to 24 h post-confluence cells was repeated
in the presence of the translation inhibitor cycloheximide [27]. Cycloheximide effectively blocked
the LTBP-2-induced elevation of TGF-β1 in the medium, indicating that the increase involved new
protein synthesis (Figure 2A). Quantitative PCR for TGF-β1 expression was also performed on RNA
extracted from MSU-1.1 cells after 15 h of incubation with exogenous LTBP-2 or BSA control (Figure 2B).
The LTBP-2-treated cells showed a fourfold elevation in TGF-β1 mRNA compared to BSA treated
controls, indicating that LTBP-2 greatly stimulated TGF-β1 expression in these fibroblasts. Overall, the
results indicate that LTBP-2 greatly upregulates the release of TGF-β1 into the culture medium, but the
mechanism primarily involves an upregulation of TGFB1 gene expression rather than an increased
secretion of existing TGF-β1 or a displacement of existing latent TGF-β1 from fibrillin-microfibrils.
2.2. Time Course for LTBP-2 Stimulation of TGF-β1 Upregulation
The optimal concentration of exogenous LTBP-2 was determined by testing a range of
concentrations from 1 to 12.5 µg/mL. The level of TGF-β1 expression appeared to saturate at a
LTBP-2 concentration of around 10 µg/mL, with TGF-β1 elevated around fourfold above the BSA
control (Figure S1). This concentration was used for all subsequent experiments unless stated otherwise.
An experiment was then conducted to determine the duration and peak for elevated TGF-β1 following
LTBP-2 stimulation. After an addition of exogenous LTBP-2, the TGF-β1 content of the medium was
measured at intervals over 24 h (Figure 3A). A significant increase in TGF-β1 above controls was
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first observed after 9 h. At the 12 h time point, the LTBP-2-treated cells showed around a twofold
increase in TGF-β1 above controls, which rose to threefold at 15 and 24 h. Since TGF-β1 secretion was
significantly higher by control cells at 24 h compared to 15 h, the TGF-β1 levels appeared to peak at
around 15 h. No significant differences were found in cell numbers in the LTBP-2-treated cultures
and untreated controls, although the cell count in all cultures had doubled after 24 h of incubation
(Figure 3B). Therefore, the LTBP-2-induced stimulation of TGF-β1 secretion was not due to a greater
increase in cell number in the LTBP-2-treated cultures.Int. J. Mol. Sci. 2017, 18, 2114  4 of 18 
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for 24 h post-confluence, then incubated for 16 h in serum-free medium with 10 µg/mL LTBP-2 or
both LTBP-2 and 10 µg/mL cycloheximide (CHX). The negative controls included 10 µg/mL BSA
or cycloheximide only. The conditioned medium was analysed for TGF-β1 content (see Materials
and Methods); (B) MSU-1.1 cells were grown to 24 h post-confluence, then incubated for 16 h with
10 µg/mL full length LTBP-2 or 10 µg/mL BSA control. Total RNA was harvested from the cells, then
reverse transcribed into cDNA for use in qPCR. The cDNA was analysed for TGF-β1, and normalized
to RNAPolII. LTBP-2 stimulated a fourfold increase in the levels of TGF-β1 mRNA compared to the
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Figure 3. Time course for LTBP-2 stimulation of TGF-β1 production. MSU-1.1 cells were grown on
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at selec ed time points. Note tha LTBP-2 had no effect on cel tion above the BSA controls.
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2.3. A Short Exposure of Cells to Exogenous LTBP-2 Is Sufficient to Stimulate TGF-β Upregulation
To determine if the LTBP-2-induced elevation of TGF-β1 was a direct effect of LTBP-2 on the
cells, we tested if a short incubation with LTBP-2 was sufficient to raise TGF-β1 levels in the medium.
MSU-1.1 cells were incubated with exogenous LTBP-2 for time periods of 10 to 60 min before the
LTBP-2 was removed by changing the medium. After 15 h, the medium was analysed for TGF-β1
content (Figure 4A). Interestingly exposure of cells to LTBP-2 for as little as 10 min caused a small but
significant increase in TGF-β1 in the medium after 15 h, suggesting that the effect was mediated by the
direct interaction of LTBP-2 with the cell surface. Exposure of the cells to LTBP-2 for 30 min and 60 min
further elevated TGF-β levels in the medium, with a 60 min exposure to LTBP-2 causing around 50%
of the increase resulting from incubation with LTBP-2 for 15 h (Figure 4A).Int. J. Mol. Sci. 2017, 18, 2114  6 of 18 
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and secretion. (A) Quantitation of TGF-β1 in the medium. MSU-1.1 cells were grown to 24 h
post-confluence, then incubated in serum-free medium with LTBP-2 (10 µg/mL) for various time
periods (10–60 min). After each incubation period, the medium was discarded and replaced with fresh
serum-free medium lacking LTBP-2. The conditioned medium was collected at 15 h and analysed
for TGF-β1 content (see Materials and Methods). The results were compared to cells incubated for
15 h with LTBP-2 or a BSA control. A significant increase in TGF-β1 was detected with as little as
10 min of exposure to LTBP-2. The mean values of three independent experiments are shown (±SD);
(B) Quantitation of TGF-β1 mRNA. At the end of each 15 h incubation above, total RNA was harvested
from the cells, then reverse transcribed into cDNA. Quantitative PCR was performed to determine
cellular TGF-β1 mRNA levels as described in materials and methods. Values were expressed relative
to the RNAP2 housekeeping gene. The control consisted of cells exposed to BSA instead of LTBP-2
for 15 h. A significant increase in TGF-β1 mRNA was detected after 15 h with as little as 10 min of
LTBP-2 exposure.
To determine if the LTBP-2 stimulated increase in TGF-β1 secretion correlated with an increased
cellular expression of TGF-β1, TGF-β1 mRNA levels in the fibroblasts were measured at 15 h after
short exposure times to LTBP-2. The cell layer was harvested after 15 h, and total RNA was extracted
and reverse transcribed for qPCR (Figure 4B). Ex osure of the cells to LTBP-2 for s littl as 10 min
resulted i a significant elevation of TGF β1 mRNA above the BSA controls. Incubation with LTBP-2
for 30 and 60 m caused addi ional increases in TGF-β1 mRNA levels, with the 60 min exposure
causing a approximately f urfo d inc ase in TGF-β1 above control cells. These results indicate that a
short exposure of MSU-1.1 cells to exogenous LTBP-2 is sufficient to stimulate TGF-β1 expression and
secretion, strongly suggesting that the process is dir ctly mediated by the interaction of LTBP-2 with
(a) cell surface receptor(s) to trigger intracellular signalling pathways.
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2.4. The TGF-β1 Stimulating Activity Maps to a Central Region of LTBP-2 Consisting of an Eight-Cys Motif
Flanked by Pairs of EGF-Like Repeats
To identify the region(s) of LTBP-2 responsible for TGF-β1 elevation, a series of LTBP-2 fragments
were tested in place of full-length LTBP-2 in exogenous addition experiments. Initially, three
recombinant fragments, designated LTBP-2NT(H), LTBP-2C(H), and LTBP-2CT(H) [14], spanning
the LTBP-2 molecule were used (Figure 5A). After 16 h, the TGF-β1 content of medium from cells
treated with fragments LTBP-2NT(H) or LTBP-2CT(H) was similar to BSA-treated controls. However,
the central fragment LTBP-2C(H) caused a significant increase in TGF-β1, similar to full-length LTBP-2
(Figure 5B), indicating that the relevant bioactive region of LTBP-2 was in the centre of the molecule
and away from known integrin binding activity in the N-terminal region [28].Int. J. Mol. Sci. 2017, 18, 2114  7 of 18 
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and on targeted individual signal pathways, namely cJUN, cFOS, AKT1/2/3, ERK, and p38 MAPK. 
These signalling molecules were selected to cover the main pathways commonly used by integrins, 
growth factors, and cytokine receptors. Western blotting (Figure 6A) showed that the treatment of 
MSU-1.1 cells with LTBP-2 (1 µg/mL) for 30 min increased the phosphorylation of serine, threonine, 
cJUN, Akt1/2/3, and p38 MAPK. However, we observed no increase in tyrosine, cFOS, and ERK 
phosphorylation. Thus, LTBP-2 seems to specifically activate signalling molecules containing 
phospho-serine and threonine, and pathways involving AKT and p38 MAPK. The experiment was 
Figure 5. A central region of LTBP-2 consisting of an 8-cys motif flanked by pairs of epidermal growth
factor (EGF)-like repeats (fragment LTBP-2C F3) contains the TGF-β1 stimulatory activity. (A) Schematic
diagram of recombinant LTBP-2 fragments. Protei fragme ts produced specifically for this study
(LTBP-2C(H) F1, F2, and F3 are highlighted within t blue box; (B) MSU-1.1 cells were grown to 24 h
post-confluence, then incubated for 16 h with full-length LTBP-2 (50 nM), molar equivalents of each of
three fragments spanning LTBP-2 (LTBP-2NT, LTBP-2C, LTBP-2CT) or BSA control. The mean values
of two independent experiments are shown (±SD); (C) Fresh cells were subsequently incubated with
each of three sub-fragments F1, F2, and F3 spanning central fragment LTBP-2C(H). In both (A) and (B),
the conditioned medium was analysed for TGF-β1 content (see Materials and Methods). The mean
values of two independent experiments are shown (±SD).
Subsequently, thr e sub-fr gments F1, F2, and F3, spann ng fragment LTBP-2C(H), wer tested
in a TGF-β1 bioassay. Only fragment F3, consisting f an 8-Cys motif flanked by two pairs of
EGF-like repeats, caused a significant increase in TGF-β1 secretion above control cells, indicating
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that it contained the TGF-β1 stimulating activity (Figure 5C). This region has no known cellular or
molecular interactions, although it is adjacent to a region containing heparin and fibroblast growth
factor-2 (FGF-2) binding activities (Fragment F2) [29,30].
2.5. Induction of Akt and p38 MAPK Phosphorylation by LTBP-2
To determine the signalling pathways involved in the stimulation of TGF-β1 expression, we
examined the effects of LTBP-2 on the phosphorylation of serine, tyrosine, and threonine generally and
on targeted individual signal pathways, namely cJUN, cFOS, AKT1/2/3, ERK, and p38 MAPK. These
signalling molecules were selected to cover the main pathways commonly used by integrins, growth
factors, and cytokine receptors. Western blotting (Figure 6A) showed that the treatment of MSU-1.1 cells
with LTBP-2 (1 µg/mL) for 30 min increased the phosphorylation of serine, threonine, cJUN, Akt1/2/3,
and p38 MAPK. However, we observed no increase in tyrosine, cFOS, and ERK phosphorylation.
Thus, LTBP-2 seems to specifically activate signalling molecules containing phospho-serine and
threonine, and pathways involving AKT and p38 MAPK. The experiment was repeated using bioactive
fragment LTBP-2C and sub-fragment LTBP-2CF3 in place of full-length LTBP-2. Phosphorylation was
quantitated relative to the no LTBP-2 control after normalisation to the total signal molecule present.
The bioactive fragments activated Akt and p38 MAPK signalling but not ERK, similar to full-length
LTBP-2 (Figure 6B,C), leading to the hypothesis that LTBP-2 may stimulate TGF-β1 expression by
activating these two signalling pathways.
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Figure 6. Exogenous LTBP-2 stimulates phosphorylation of AKT and p38 mitogen-activated protein
kinase (MAPK) in human fibroblasts. (A) MSU-1.1 cells (1 × 105 cells/well) were treated with or
without LTBP-2 (10 µg/mL) for 30 min. Total cell lysates were immunoblotted for phosphorylation
of candidate signalling molecules, including phospho-serine, phospho-tyrosine, phospho-threonine,
phospho-p38 MAPK, phospho-Akt1/2/3, phospho-ERK, c-FOS, c-JUN, and for β-actin internal control
as described in ma erials and methods. Note that ther was maj phosphorylation of p38 MAPK
and AKT1/2/3, but no stimulation of ERK or cFOS; (B) Cells were treated for 30 min with full-length
LTBP-2 or with molar equivalents of fragments containing TGF-β1 stimulating activity, LTBP-2C(H), or
LTBP-2C(H) F3. Cell lysates were immunoblotted for total and phosphorylated p38 MAPK, Akt1/2/3,
and ERK; (C) The ratio of phospho-protein to total protein for each signal molecule from each treatment
is expressed relative to the average value from no LTBP-2 control cells (given an arbitrary value of 1.0).
Similar results were ob erved in replicate experiments.
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2.6. LTBP-2 Stimulates the Expression of TGF-β1 via Akt and p38 MAPK Signalling Pathways
Specific inhibitors were used to determine if the LTBP-2-induced phosphorylation of AKT1/2/3
and/or p38 MAPK caused an upregulation of TGF-β1. MSU-1.1 cells treated with or without
LTBP-2 were cultured in the presence of an Akt phosphorylation inhibitor, GSK690693 or AZD5363,
or a p38 MAPK phosphorylation inhibitor, SB202190 or VX-702, and TGF-β1 in the medium was
measured by ELISA after 16 h (Figure 7). The LTBP-2-induced upregulation of TGF-β was inhibited by
AKT phosphorylation inhibitors GSK690693 and AZD536310, and inhibited by p38 MAPK inhibitor
(SB202190) but not inhibitor VX-702. SB202190 blocks phosphorylation of both the α and β forms of
p38 MAPK, whereas VX-702 blocks only the α isoform [31]. Thus, it appears that the LTBP-2-induced
upregulation of TGF-β1 involves AKT1/2/3 and p38β MAPK.
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MSU-1.1 cells were grown to 24 h post-confluence, then incubated in serum-free medium with or
without inhibitor (10 µM) of Akt (GSK690693 or AZD536310) or p38 MAPK (VX-702 or SB202190)
for 2 h, followed by an addition of 50 nM of LTBP-2 or bioactive fragment LTBP-2C F3. Incubati n
was continued for a further 15 h, and the conditioned medium was nalysed for TGF-β1 content
(see Materials and Methods). Controls involved incubations with individual inhibitors or BSA in the
abs ce of LTBP-2. The mean values ± SD from duplicate experiments are shown.
2.7. Blocking of Integrin αVβ3 Receptors Partially Attenuates TGF-β1 Production by LTBP-2
To determine if an integrin was involved in the upregulation of TGF-β, a range of established
blocking antibodies was tested in the LTBP-2 stimulation assay (Figure 8A). Antibodies to the β1 and
αVβ5 integrins had no effect on LTBP-2 upregulation of TGF-β1, indicating that the large family of β1
integri s and αVβ5 int grin were not evidently involved in the process. Intriguingly, the anti-αVβ3
integrin a tibo y (10 µg/mL) showed partial inhibitio of the TGF-β1’s upregulation. I a subs quent
experim nt, doubling of the anti-αVβ3 antibody concentration and reducing the concentratio of
LTBP-2F3 10-fold showed only a very minor further attenuation, suggesting that the inhibitory effect
of the antibody was close to saturation (Figure 8B). Even under these conditions, LTBP-2 still elevated
TGF-β lev ls to double the amount in c ntrol cultures. This s ggested that αVβ3 int grin alone was
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not responsible for the signal transmission and that another primary receptor was involved, perhaps
in conjunction with αVβ3, to mediate TGF-β1 upregulation by LTBP-2.
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and αVβ5 (10 µg/mL) for 2 h. Incubation was continued for 15 h with the addition of a bioactive
LTBP-2 fragment (LTBP-2C(H) or LTBP-2C(H) F3) 50 nM final concentration), a d the conditioned
medium was analysed for TGF-β1 content (see Materials and Methods). Co trol incubations included
LTBP-2 or a bioactive fragment without antibody and BSA in the absence of LTBP-2. The mean values
of two independent experiments are sh wn (±SD); (B) Increasi g the concentration of anti-integrin
αVβ3 antibody caused little further attenuation of LTBP-2-i duc d TGF-β1 upregul tion. The above
exper ment w s r peated including two conce trations of anti-integrinαVβ3 (10 µg/mL and 20 µg/mL)
during a 2 h pre-incubation a d for a further 15 h following an addition of a LTBP-2 C F3 fragment
(5 nM final co centration). The conditioned medium was then analysed for TGF-β1 content (see
Materials and Methods). Controls nvolved incubation of c lls with nti-integrin antib dy only or BSA.
Mean valu s ±SD from triplicate wells are shown. Doubling of the anti αvβ3 a tibody concentration
caused only a very slight additional reduction in TGF-β stimulation, suggesting that the blocking effect
was close to satur tion. The mean values of two ndepen ent experiments are shown (±SD).
3. Discussion
To our knowledge, the current study is the first to investigate the mechanism of TGF-β regulation
by LTBP-2. Our initial hypothesis was that excess LTBP-2 would compete with LTBP-1 for binding
and release the TGF-β1 complex f om it storage sites in the matrix. This was investigated by an
incubation of exogenous LTBP-2 with MSU-1.1 cells hat had elaborated an extensive network o
fibrillin-microfibrils. A protein causing the release of TGF-β complexes from matrix torage w s
previously documented by Cha dhry et al., w o found that a fragment of fibrillin-1 caused a significant
increase in TGF-β1 bioavailability by inhibiting the binding of LTBP-1 to fibrillin microfibrils [32]. Our
ex eriments sh wed a significant increase in latent TGF-β1 in the culture edium, but there was no
significant decrease in TGF-β1 in the cell layer. Moreover, repeating the experiment with cell cultu es
containing a very limited mat ix gave a similar re ult, suggesting that an al rnative mechanism was
responsible for the elevatio of TGF-β1. An additio of cycloheximide block d the increase in TGF-β1,
confirming that new protein synthesis was required. Exogenous LTBP-2 was subsequently shown o
cause a fourfold incre se in TGF-β1 mRNA in the fibroblasts, confirming that the increase in TGF-β1
in the medium was due to an increased expression and secretion of new TGF-β1 rather than a rel ase
of matrix-stored growth factor. Following an ddition of exogenous LTBP-2, the increase in TGF-β1
could only be detect d after 9 h, and TGF-β1 levels peaked at aro nd 15 h. This long time frame is
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consistent with LTBP-2 stimulating TGFB1 gene expression and the secretion of new TGF-β1 into the
medium. This result contrasts with the Chaudhry et al. study, where a fibrillin fragment displaced
TGF-β1 from matrix storage after as little as 10 min [32].
Exposure of MSU-1.1 cells to exogenous LTBP-2 for only 10 min resulted in increased TGF-β1
expression and secretion, strongly suggesting that LTBP-2 was directly interacting with the cells via
(a) receptor(s), or possibly an integrin, to elicit the response rather than displacing other bioactive
molecules, such as growth factors, from matrix storage. Since LTBP-2 has known integrin-binding
activity [28], it was important to determine if the TGF-β1 upregulation involved known LTBP-2-cell
interactions. The TGF-β1 stimulating bioactivity was principally confined to a short region in the
centre of LTBP-2, consisting of an 8-Cys motif flanked on each side by a pair of EGF-like repeats
(fragment F3) (see Figure 5A). This was clearly distinct from the integrin binding site with affinity
for the integrins α3β1 and α6β1, situated towards the N-terminus [28]. To determine if an integrin
was, or integrins were, involved in LTBP-2-induced TGF-β1 upregulation, we included inhibitory
antibodies to block specific integrin activity throughout the bioassay. Antibodies to the integrins
αVβ5 and β1 showed no inhibitory effect. An anti-αVβ3 integrin antibody partially inhibited LTBP-2
upregulation of TGF-β1, which was surprising since no RGD sequence is present in the bioactive
LTBP-2 sequence. However, only partial blocking of the TGF-β1 upregulation occurred even with a
large excess of anti-αVβ3 antibody. This suggested that, while the LTBP-2 bioactivity may indirectly
involve active αVβ3 integrin, another main receptor was, or other main receptors were, responsible
for primary signal transmission. Integrins can stimulate signalling pathways independently, but more
often they act synergistically with other receptors to elicit a full signalling response [33,34]. Specific
integrins can interact with receptors for vascular endothelial growth factor, TGF-β, insulin, EGF, and
platelet-derived growth factor-β, or with cell surface heparan sulphate proteoglycans (HSPGs) [35].
The integrin αVβ3 modulates platelet-derived growth factor-β, a potent stimulator of cell motility, and
this interaction appears to have an antagonistic effect on the reactive oxygen species production at focal
adhesion sites [36]. In addition, the α5β1 integrin interacts with the cell surface HSPG, syndecan-4, to
regulate matrix structure and cell adhesion during development and in most adult tissues [37]. It is
possible that the bioactive region of LTBP-2 (fragment F3) binds to an unidentified main receptor or
co-receptor in complex with the αVβ3 integrin. The bound anti-αVβ3 antibody might partially obscure
the binding of LTBP-2 to its main receptor without LTBP-2 being a direct ligand for the αVβ3 integrin.
We also investigated if any major intracellular signalling pathways were activated by LTBP-2
resulting in TGF-β upregulation. LTBP-2 increased the phosphorylation of specific signalling
proteins, namely p38 MAPK and Akt1/2/3 (but not ERK). The use of specific inhibitors indicated
that both molecules were important LTBP-2-induced upregulation. The p38 MAPK family
consists of four members, p38α p38β, p38γ, and p38δ [38]. P38 MAPK is strongly activated by
such stimuli as environmental stress, inflammatory cytokines, and growth factors [38], and is
involved in pathological conditions including inflammation, rheumatoid arthritis, cancer, cardiac
hypertrophy, neurodegenerative disorders, and fibrosis [39]. Only p38β inhibitor (SB2021900) inhibited
LTBP-2-induced TGF-β1 upregulation, indicating that this isoform is involved in the cascade. A main
feature of p38β MAPK activation is sustaining cell survival [40]. For example, P38β MAPK induces a
potent anti-apoptotic factor in the synovial membrane of rheumatoid arthritis patients [41]. Activation
of p38β MAPK is important in the anti-inflammatory, anti-proliferative, and anti-apoptotic effects of
carbon monoxide in various models [42].
Akt1/2/3 is a family of serine/threonine-specific protein kinases that plays key roles in the
regulation of cell survival, cell cycle, and growth [43]. Akt signalling components are frequently
altered in human cancers and in fibrosis [44,45]. For instance, Li et al., demonstrated that Akt pathway
activation promoted collagen production and scar formation in acute muscle contusion [46]. Akt
pathway activation can also promote lung fibroblast proliferation and pulmonary fibrosis by enhancing
macrophage survival [47]. Interestingly, inhibitor GSK690693 more markedly blocked the upregulation
of TGF-β1 by Akt phosphorylation compared to inhibitor AZD536310. GSK690693 (IC 50 = 2 nM) is a
Int. J. Mol. Sci. 2017, 18, 2114 11 of 17
more potent Akt1 inhibitor than AZD5363 (IC 50 of 3 nM), suggesting that Akt1 may be the main Akt
isoform involved here. Akt1 is associated with altered cell invasion and migration, and is a frequently
activated protein kinase in cancers [48] where it enhances the invasion capability of cancer cells. Akt is
considered a potential therapeutic target for several cancer types [49]. Akt1 is also linked to cardiac
fibrosis by promoting inflammatory response in early stages of hypertensive heart disease [50].
From our study, both Akt and p38β MAPK appear to be essential for TGF-β1 upregulation
by LTBP-2, which is consistent with other studies linking these pathways to TGF-β1 regulation.
Blockade of the Ras/PI3K/Akt pathways reduced the expression of TGF-β as an angiogenic factor
in mouse osteosarcoma [51] and suppressed TGF-β1 production by macrophages treated with
phophatidylserine-liposomes [52]. Interestingly, Xiao et al., showed that apoptotic cells upregulate
TGF-β mRNA transcription via activation of the p38 MAPK pathway and TGF-β1 mRNA translation
via activation of the Akt pathway [53]. If LTBP-2 used similar mechanisms to upregulate TGF-β1
expression, it would explain why extensive inhibition was observed by the blocking of either p38
MAPK or Akt. It should be noted that we have not established that the LTBP-2-induced p38 MAPK
and Akt phosphorylation leads to a direct stimulation of TGF-β1 expression. Given the observed delay
of several hours in TGF-β1 upregulation by LTBP-2, it is possible that expression of (an) intermediate
protein(s) is stimulated that in turn upregulates the expression of TGF-β1. It is noteworthy that a
very recent paper has shown that LTBP-2 knockdown inhibits invasion and tumorigenesis in thyroid
cancer cells and this involves the PI3K/Akt signalling pathway [54]. Further elucidation of the above
pathways and their control mechanisms will enhance our knowledge of fibrosis and other diseases
associated with TGF-β dysregulation.
It is interesting that full-length LTBP-2 and the larger fragment LTBP-2C caused a stronger
activation and phosphorylation of the Akt and p38 MAPK signalling pathways than the smaller
fragment LTBP-2 F3. This suggests that a region adjacent to F3 may enhance its signalling properties,
perhaps by positively influencing the binding of LTBP-2 to the cell surface. A candidate molecule
for this is a cell surface HSPG. Various HSPGs are found at the cell surface and/or the extracellular
matrix and play important roles as cell receptors and co-factors, and they can act in conjunction
with integrins to modulate cell behaviour and signalling outcomes, often through growth factor
receptor signalling pathways [33,35,55]. Interestingly, our recent studies revealed that LTBP-2 binds
strongly to HSPGs, including cell-signalling, transmembrane syndecan-4, with multiple binding sites
within the N-terminal region of LTBP-2 and one site (in fragment LTBP-2F2) adjacent to the TGF-β
stimulating region (fragment LTBP-2F3) [30]. Binding of LTBP-2 to HSPG via this adjacent site may
explain the stronger signalling invoked by full-length LTBP-2 and fragment LTBP-2C than by LTBP-2F3,
which lacks HSPG-binding activity. The concepts are illustrated schematically in Figure 9. Further
research is needed to elucidate the full nature of LTBP-2 interaction(s) with the cell surface required for
TGF-β1 upregulation.
The identification of the LTBP-2 receptor involved in TGF-β1 upregulation may prove difficult.
For instance, the Akt signaling cascade can be activated by a variety of integrins, cytokine receptors,
immune cell receptors, receptor tyrosine kinases, and G-protein-coupled receptors [56]. At face
value, the results indicate that receptor(s) not signalling primarily via ARK or p38 are unlikely to be
prime candidates for the unidentified LTBP-2 receptor. For example, growth factors EGF, FGF, and
Platelet-Derived Growth Factor primarily use ERK pathways [57,58], and the TGF-β/BMP family uses
the SMAD signalling cascade [59]. However, such growth factors can also use non-canonical pathways;
EGF can stimulate Akt via mTORC2 [60], and TGF-β1 can use several signalling pathways involving
p38, Akt, or ERK [59,61]. Therefore, caution is required when eliminating possible candidates for the
unidentified LTBP-2 receptor.
Since TGF-β1 plays a key role in the proliferative phase of wound healing and in fibrosis [62], it
is possible that the TGF-β1 upregulation by LTBP-2 in fibroblasts plays some role in fibrotic disease
processes and in genetic disorders which have fibrotic components, such as WMS [20]. We have
recently shown that LTBP-2 is highly expressed in fibrotic skin conditions, keloids, and hypertrophic
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scars [29,63]. Interestingly, LTBP-2 co-localised in these tissues with another growth factor, FGF-2.
LTBP-2 is a potent inhibitor of FGF-2 activity via a single high-affinity binding site in the fragment
LTBP-2CF2 [29,63]. This region corresponds to a LTBP2 gene mutation linked to a case of WMS [20].
It is possible that elevated LTBP-2 might influence FGF-2 bioactivity during wound repair and healing
processes and in fibrosis. Clearly, more research is required to fully establish the influence of LTBP-2
on TGF-β1 and FGF-2 bioactivities in fibrosis and fibrotic diseases.Int. J. Mol. Sci. 2017, 18, 2114  13 of 18 
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4. Materials and Methods 
4.1. Reagents 
LTBP-2 and fragments were produced using the pCEP4 expression vector in 293EBNA cells as 
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4. Materials and Methods
4.1. Reagents
LTBP-2 and fragments were produced using the pCEP4 expression vector in 293EBNA cells as
described previously [14,29,30]. Gels showing the size and purity of each fragment have been published
elsewhere [29]. Antibodies against p-Akt1/2/3 (Ser473), Akt1/2/3 (H-136), p-p38 (D-8), p38 (H-147),
p-ERK (E-4), ERK (MK1), and β-actin (C4) were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA); Dylight-800 labelled anti-mouse and anti-rabbit IgGs were from Thermo Scientific, Waltham,
MA, USA. Rabbit anti-[human LTBP-2 peptide] antibody 3504 has been described previously [14].
Signalling inhibitors SB202190 and VX-702 for p38 MAPK and GSK690693 and AZD5363 for Akt were
from Selleckchem, (Houston, TX, USA). Blocking antibodies for β1 integrin (P4C10) and αVβ3 integrin
(CD51/61) were from Millipore (Temecula, CA, USA); anti-αVβ5 integrin (P1F6) was from Abcam
(Cambridge, UK).
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4.2. Cell Culture and Treatment
His6-tagged full-length r-LTBP-2 and contiguous fragments were produced in 293-EBNA cells and
purified from serum-free culture medium by using Ni-Sepharose as described previously [14,29,30].
Purified recombinant proteins were dialyzed into tris-buffered saline (TBS)–0.5 M NaCl and analysed
by gel electrophoresis and immunoblotting to confirm size and purity.
MSU-1.1 fibroblasts were grown for up to 3 weeks post-confluence in 6-well plates in Dulbecco’s
Modified Eagle’s Medium plus 10% FCS at 37 ◦C. The cells were incubated for various times (3–24 h)
in serum-free medium with r-LTBP-2 (final concentration 2.5–12.5 µg/mL). For control wells, BSA
was added instead of LTBP-2. In some instances, protein synthesis was inhibited with cycloheximide
(10 µg/mL) (Sigma, St. Louis, MO, USA). In the signalling studies, cells were pre-incubated for
2 h with Akt or p38 MAPK inhibitors (10 mM) prior to an addition of LTBP-2. The cell layer was
resuspended in 1 mL PBS, and treated with 1 M HCl (200 µL) to activate latent TGF-β. After 10 min,
the suspension was neutralised with 1.2 M NaOH/0.5 M HEPES. After centrifugation for 5 min at
350 g, the supernatant was analysed for TGF-β1 content by ELISA.
In the initial integrin study, the cells were pre-incubated for 2 h with blocking antibodies to integrin
β1, αVβ3, or αVβ5 (10 µg/mL) prior to an addition of LTBP-2, fragment LTBP-2C, or fragment LTBP-2
F3 (50 nM). The cells were then incubated for 15 h in the presence of antibody. For control wells, BSA
(10 µg/mL) was added instead of LTBP-2. The TGF-β1 content of the medium was determined by
ELISA. In the subsequent experiment cells were incubated with fragment LTBP-2 F3 at 5 nM and
anti-αVβ3 at 10 µg/mL or 20 µg/mL.
4.3. Detection and Quantitation of TGF-β
The TGF-β1 content of conditioned medium was determined using the DuoSet ELISA for human
TGF-β1 (R&D Systems, Minneapolis, MN, USA), following the manufacturer’s instructions. Briefly,
wells were coated with mouse anti-TGF-β1 (200 ng in PBS) and incubated for 18 h. The wells were
washed with 0.05% Tween 20 in PBS, blocked with 5% Tween 20 in PBS for 1 h, and incubated with
conditioned medium (100 µL) for 2 h. Control wells were incubated with fresh medium. For standard
curves, wells were incubated with TGF-β1 (100 µL) (31.3 to 2000 pg/mL) in 1.4% BSA in PBS. With
washing between steps, wells were incubated with 100 µL of biotinylated chicken anti-human TGF-β1,
(300 ng/mL) for 2 h, then streptavidin-horseradish peroxidase (100 µL) for 20 min, followed by 100 µL
Substrate Solution (R&D Systems) for 20 min, in reduced lighting. The reaction was stopped with
50 µL 1 M H2SO4, and absorbance (450 nm) was measured using a Titertek Multiscan microplate
reader (Flow Laboratories).
4.4. Quantitative PCR
Total RNA was extracted from cells using trizol (Invitrogen, California, CA, USA), following
the manufacturer’s instructions. RNA samples were treated with DNase 1 (RQ1 DNase, Promega,
Fitchburg, WI, USA) and recovered using the RNEasy Mini Kit (Qiagen, Düsseldorf, Germany).
Total RNA (1 µg) was reverse transcribed using Superscript III (Invitrogen, Carlsbad, CA,
USA). The cDNA was PCR-amplified using a SYBR-Green kit (Qiagen). Primer sequences
(forward and reverse respectively) were as follows: TGF-β 5′-CTCCGAGAAGCGGTACCTGAAC-3′,
and 5′-CACTTGCAGTGTGTTATCCCT-3′; LTBP-2 5′-GGGCACCGCACCACCTACACG-3′ and
5′-TCATCACACTCATTCACATCTACG-3′; RNAPolII 5′-AGGGGCTAACAATGGACACC-3′ and
5′-CCGAAGATAAGGGGAACTACT-3′. The housekeeping gene RNAP2 was used as the internal
standard. PCR was performed with a hot start at 95 ◦C for 10 min, followed by 40 cycles of denaturation
at 95 ◦C for 20 s, annealing at 60 ◦C for 20 s, and extension at 72 ◦C for 45 s.
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4.5. Measurement of Signal Phosphorylation
MSU-1.1 cells (4 × 105 cells/well) were treated with LTBP-2 (50 nM, 10 µg/mL) for 30 min.
Cells were then lysed with 50 mM Tris buffer (pH 6.8) containing 0.5% SDS and 2 mM EDTA plus
phosphatase and protease inhibitors (#04906837001 and #11836153001, Roche Diagnostics, Basel,
Switzerland). The protein content of cell extracts was measured using a BCA Kit (Thermo Fisher
Scientific, Waltham, MA, USA). Extracted protein (50 µg) was analysed on 12% gels and transferred
to nitrocellulose (Pall Corporation, Port Washington, NY, USA). The membrane was blocked with
10% milk in tris-buffered saline (TBS) for at least 1 h and then incubated with a primary antibody to a
phosphorylated or total signalling molecule (AKT, P-38 MAPK, or ERK) in 2% milk at 4 ◦C overnight.
The membrane was washed in TBS then incubated with secondary anti-rabbit IgG or anti-mouse IgG
antibodies conjugated with IR800 fluorescence dye, (1:5000 dilution), in 3% milk for 1 h. Membranes
were imaged with the LI-COR Odyssey Infrared Imaging System. Bands were quantitated using
ImageJ 1.48 software (NIH, Bethesda, MD, USA) and normalised to the internal β-actin signal or total
protein. For comparison of the phospho- and total signals, the ratio of normalised phospho-protein
signal to the total protein signal was expressed in arbitrary units relative to the average value from
cells incubated without LTBP-2 treatment (equalling 1).
4.6. Statistical Analysis
The data from in vitro TGF-β stimulation assays, cell count assays, Western blot quantitation, and
qPCR were statistically analysed using a paired Student’s t-test with GraphPad Prism 7.02 software.
A p value ≤ 0.05 was regarded as statistically significant.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/10/2114/s1.
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LTBP-2 Latent Transforming Growth Factor β-1 Binding Protein 2
TGF-β Transforming Growth Factor β
EGF Epidermal Growth Factor
FGF Fibroblast Growth Factor
MAPK Mitogen-Activated Protein Kinase
TBS tris-Buffered Saline
PBS Phosphate-buffered Saline
BSA Bovine Serum Albumin
ELISA Enzyme-Linked Immunosorbent Assay
HSPG Heparan Sulphate Proteoglycan
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